Therapeutics Targeting the Gut Microbiome: Rigorous Pipelines for Drug Development
- PMID: 32053786
- DOI: 10.1016/j.chom.2020.01.022
Therapeutics Targeting the Gut Microbiome: Rigorous Pipelines for Drug Development
Abstract
Restoration of the gut microbiome is a promising preventive and therapeutic strategy in a number of clinical scenarios. We discuss here the scientific and clinical challenges of engineering and implementing these strategies.
Copyright © 2020. Published by Elsevier Inc.
Conflict of interest statement
Declaration of Interests M.R.M.v.d.B. has received research support from Seres Therapeutics; has consulted, received honorarium from, or participated in advisory boards for Seres Therapeutics, Flagship Ventures, Novartis, Evelo, Jazz Pharmaceuticals, Therakos, Amgen, Magenta Therapeutics, WindMIL Therapeutics, Merck & Co, Inc., Acute Leukemia Forum (ALF), and DKMS Medical Council (Board); and has IP Licensing with Seres Therapeutics and Juno Therapeutics. J.U.P. reports research funding, intellectual property fees, and travel reimbursement from Seres Therapeutics and consulting fees from DaVolterra.
Comment on
-
Regulatory Considerations for Fecal Microbiota Transplantation Products.Cell Host Microbe. 2020 Feb 12;27(2):173-175. doi: 10.1016/j.chom.2020.01.018. Cell Host Microbe. 2020. PMID: 32053787 Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources